Attached files
| file | filename |
|---|---|
| EX-10.12 - AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND BO - IMMUCELL CORP /DE/ | f10k2020ex10-12_immucell.htm |
| EX-31 - CERTIFICATION - IMMUCELL CORP /DE/ | f10k2020ex31_immucell.htm |
| 10-K - ANNUAL REPORT - IMMUCELL CORP /DE/ | f10k2020_immucellcorp.htm |
| EX-32 - CERTIFICATION - IMMUCELL CORP /DE/ | f10k2020ex32_immucell.htm |
| EX-4.2 - DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE - IMMUCELL CORP /DE/ | f10k2020ex4-2_immucell.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Nos. 333-214641 and 333-228479) on Form S-3 and the Registration Statements (Nos. 333-02631, 333-65514, 333-167721 and 333-237428) on Form S-8 of ImmuCell Corporation of our report dated March 30, 2021, relating to the financial statements of ImmuCell Corporation, appearing in this Annual Report on Form 10-K of ImmuCell Corporation for the years ended December 31, 2020 and 2019.
| /s/ WIPFLI LLP | |
| South Portland, Maine | |
| March 30, 2021 |